Suchergebnisse - "Pan, Hongming"

PubPharm (313)

1

A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Wei, X. | Zou, Z. | Zhang, W. | +21

2

First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors

enthalten in: BMC cancer | 2024

von Guo, Y. | Wang, Z. | Zhou, H. | +15

3

First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors

enthalten in: BMC cancer | 2024

von Guo, Y. | Wang, Z. | Zhou, H. | +15

4

Exploration and machine learning model development for T2 NSCLC with bronchus infiltration and obstructive pneumonia/atelectasis

enthalten in: Scientific reports | 2024

von Jin, X. | Pan, Y. | Zhai, C. | +3

5

The Gastric Cancer Immune Prognostic Score (GCIPS) Shows Potential in Predicting an Unfavorable Prognosis for Gastric Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment

enthalten in: Biomedicines | 2024

von Zuo, Y. | Sun, H. | Pan, H. | +3

6

Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification : Preclinical and Clinical Evidence

enthalten in: JCO precision oncology | 2024

von Qin, S. | Pan, H. | Blanc, J. | +9

7

SAFFRON-103 : a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma

enthalten in: Immunotherapy | 2024

von Wang, X. | Pan, H. | Cui, J. | +9

8

Autophagy in colitis-associated colon cancer : exploring its potential role in reducing initiation and preventing IBD-Related CAC development

enthalten in: Autophagy | 2024

von Jin, X. | You, L. | Qiao, J. | +2

9

Association of frailty with mortality in cancer survivors : results from NHANES 1999-2018

enthalten in: Scientific reports | 2024

von Zhai, C. | Yin, L. | Shen, J. | +4

10

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations : cohort 2 of the randomized phase III THOR trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Siefker-Radtke, A. | Matsubara, N. | Park, S. | +113

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[32]